Publications 2024

Ilmarinen T, Bratland Å, Tøndel H, Guðjónsson A, Gebre-Medhin M, Palmgren B, Mäenpää H, Bjørndal K, Grau Eriksen J (2024)
Current aspects of the quality of head and neck cancer care - survey of the Scandinavian Society for Head and Neck Oncology
Acta Otolaryngol, 144 (5-6), 404-408
DOI 10.1080/00016489.2024.2386097, PubMed 39109489

Kristensen MH, Holm AIS, Hansen CR, Zukauskaite R, Samsøe E, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, Andersen M, Overgaard J, Eriksen JG (2024)
High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma - A DAHANCA 19 study
Clin Transl Radiat Oncol, 46, 100772
DOI 10.1016/j.ctro.2024.100772, PubMed 38596816

Kristensen MH, Sørensen MK, Tramm T, Alsner J, Sørensen BS, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, Andersen M, Lilja-Fischer JK, Holm AIS, Samsøe E, Hansen CR, Zukauskaite R, Overgaard J, Eriksen JG (2024)
Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study
Radiother Oncol, 193, 110149
DOI 10.1016/j.radonc.2024.110149, PubMed 38341096

Publications 2023

Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM, Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Ge J, Gumuscu B, Swaby RF, Gutzmer R (2023)
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
Dermatol Ther (Heidelb), 13 (12), 3165-3180
DOI 10.1007/s13555-023-01059-y, PubMed 37943491

Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R (2023)
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
JAMA Oncol, 9 (6), 779-789
DOI 10.1001/jamaoncol.2023.0147, PubMed 37022706

Rohde M, Eriksen JG, Pareek M, Bratland Å, Mäkitie A, Hammarstedt-Nordenvall L, Wessel I, Lybeck JS, Mäenpää H, Gebre-Medhin M, Godballe C (2023)
Diagnosis of locally recurrent head and neck squamous cell carcinoma in the Nordic HNC centers and feasibility of the Odense-Birmingham definition
Acta Oncol, 62 (9), 1102-1105
DOI 10.1080/0284186X.2023.2245550, PubMed 37602835

Publications 2022

Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K (2022)
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
J Clin Oncol, 40 (21), 2321-2332
DOI 10.1200/JCO.21.02198, PubMed 35333599

Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D (2022)
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
J Clin Oncol, 41 (4), 790-802
DOI 10.1200/JCO.21.02508, PubMed 36219809

Nyrud MK, Bratland Å, Landrø L, Brevig T, Ryder T, Hermann R, Frich L (2022)
Merkel cell carcinoma
Tidsskr Nor Laegeforen, 142 (9)
DOI 10.4045/tidsskr.21.0693, PubMed 35699540

Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B (2022)
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Oral Oncol, 128, 105815
DOI 10.1016/j.oraloncology.2022.105815, PubMed 35381576

Publications 2020

König M, Osnes T, Bruland Ø, Sundby Hall K, Bratland Å, Meling TR (2020)
The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
Front Oncol, 10, 1402
DOI 10.3389/fonc.2020.01402, PubMed 32850452

Witt Nyström P, Bratland Å, Minn H, Grau C (2020)
Ongoing and future clinical trials in particle therapy in the Nordic countries
Acta Oncol, 59 (10), 1145-1150
DOI 10.1080/0284186X.2020.1792548, PubMed 32673134

Publications 2019

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D, KEYNOTE-048 Investigators (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Lancet, 394 (10212), 1915-1928
DOI 10.1016/S0140-6736(19)32591-7, PubMed 31679945

König M, Osnes T, Bratland Å, Jebsen P, Meling TR (2019)
Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study
J Neurol Surg B Skull Base, 81 (6), 627-637
DOI 10.1055/s-0039-1694050, PubMed 33381366

König M, Osnes T, Bratland Å, Meling TR (2019)
Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience
J Neurol Surg B Skull Base, 81 (6), 664-672
DOI 10.1055/s-0039-1694967, PubMed 33381371

Publications 2017

Mäkitie AA, Cange HH, Hammarstedt-Nordenvall L, Gudjonsson A, Jóhannsson J, Laranne J, Mäenpää H, Rikardsen O, Bratland Å, Wessel I, Johansen J, Grau C (2017)
Head and neck cancer management in the Nordic countries: an effort to harmonize treatment
Eur Arch Otorhinolaryngol, 274 (5), 2363-2365
DOI 10.1007/s00405-017-4456-4, PubMed 28124110

Publications 2016

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Eur Heart J, 37 (21), 1671-80
DOI 10.1093/eurheartj/ehw022, PubMed 26903532

Publications 2014

von der Lippe C, Roscher I, Nordgarden H, Rustad C, Larsen SM, Mjøen E, Bratland Å (2014)
Man with macrocephaly, learning disability and multiple basal cell carcinomas
Tidsskr Nor Laegeforen, 134 (11), 1151-4
DOI 10.4045/tidsskr.13.0894, PubMed 24939783

Publications 2013

Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
[Cardioprotective treatment during adjuvant cancer therapy]
Tidsskr Nor Laegeforen, 133 (17), 1832-6
DOI 10.4045/tidsskr.12.1514, PubMed 24042297

Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH (2013)
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer
PLoS One, 8 (5), e63723
DOI 10.1371/journal.pone.0063723, PubMed 23675504

Publications 2012

Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
Cardiology, 123 (4), 240-7
DOI 10.1159/000343622, PubMed 23207160

Publications 2011

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
DOI 10.1186/1748-717X-6-33, PubMed 21473790

Publications 2010

Bratland A, Vetrhus T, Grøholt KK, Ree AH (2010)
Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases
Acta Oncol, 49 (1), 42-9
DOI 10.3109/02841860903081897, PubMed 20100143

Publications 2009

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
Clin Exp Metastasis, 26 (5), 485-96
DOI 10.1007/s10585-009-9248-9, PubMed 19294521

Bratland Å (2009)
Therapeutic targeting of molecular mechanisms involved intumor progression and metastasis
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 729, 1 b. (flere pag.)
BIBSYS 090439821, ISBN 978-82-8072-446-5

Publications 2008

Ree AH, Bratland A, Dueland S (2008)
[Molecular targeted therapy in colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 190-3
PubMed 18202731

Publications 2006

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
Radiat Oncol, 1, 25
DOI 10.1186/1748-717X-1-25, PubMed 16887021

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124

Publications 2005

Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
Mol Cancer Ther, 4 (8), 1231-8
DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439

Publications 2004

DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA (2004)
Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
J Steroid Biochem Mol Biol, 92 (5), 365-74
DOI 10.1016/j.jsbmb.2004.07.011, PubMed 15698541

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
Radiother Oncol, 72 (3), 305-10
DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729

Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
Anticancer Res, 24 (2B), 555-62
PubMed 15160994

Publications 2003

Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH (2003)
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
Clin Exp Metastasis, 20 (6), 541-7
DOI 10.1023/a:1025860214891, PubMed 14598888

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø (2003)
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
Oncogene, 22 (55), 8952-5
DOI 10.1038/sj.onc.1207000, PubMed 14654792

Publications 2002

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869

Publications 1999

Bratland Å (1999)
Tekstil kulturarv i ryggen - for framtida
Høgskulen i Telemark, Avdeling for estetiske fag og folkekultur, [Notodden], 133, [45] bl.
BIBSYS 991343107